Thyroid Cancer - Pipeline Review, H2 2014

Date: November 30, 2014
Pages: 110
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TADA7BFCA39EN
Leaflet:

Download PDF Leaflet

Thyroid Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Thyroid Cancer - Pipeline Review, H2 2014’, provides an overview of the Thyroid Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Thyroid Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Thyroid Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Thyroid Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Thyroid Cancer Overview
Therapeutics Development
Pipeline Products for Thyroid Cancer - Overview
Pipeline Products for Thyroid Cancer - Comparative Analysis
Thyroid Cancer - Therapeutics under Development by Companies
Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes
Thyroid Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Thyroid Cancer - Products under Development by Companies
Thyroid Cancer - Products under Investigation by Universities/Institutes
Thyroid Cancer - Companies Involved in Therapeutics Development
AstraZeneca PLC
Azaya Therapeutics Incorporated
Bio-Path Holdings, Inc.
Biovista Inc.
centrose llc
Ecrins Therapeutics SAS
Eisai Co., Ltd.
GlaxoSmithKline plc
Novartis AG
Translational Therapeutics, Inc.
Trophogen, Inc.
Vascular Biogenics Ltd.
Thyroid Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BP-100-1.02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVA-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BVA-701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
docetaxel liposomal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EDC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETD-5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2256098 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenvatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MVX-ONCO-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panobinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Agonize VEGF for Thyroid and Multiple Other Cancers - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selumetinib sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize ALK for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit PAK for Thyroid Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TR-1401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRX-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VB-111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thyroid Cancer - Recent Pipeline Updates
Thyroid Cancer - Dormant Projects
Thyroid Cancer - Discontinued Products
Thyroid Cancer - Product Development Milestones
Featured News & Press Releases
Nov 26, 2014: Eisai Opens Multi-million Pound High Tech Global Potent Packaging Facility For New Cancer Treatment in Hatfield, UK
Oct 14, 2014: U.S. FDA Grants Eisai's Investigational Agent Lenvatinib Priority Review Designation for the Treatment of Advanced Thyroid Cancer
Sep 17, 2014: Eisai to Present Clinical Data on Lenvatinib at 39th ESMO Congress
Sep 06, 2014: Significant Improvement in Progression-Free Survival With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer: Data Confirmed in New Subgroup Analyses
Aug 18, 2014: Eisai submits Marketing Approval Application for Anti cancer Agent Lenvatinib Simultaneously in Europe And U.S.
Jul 31, 2014: Ema Accepts Eisai's Request For Accelerated Assessment Of Anticancer Agent Lenvatinib
Jun 26, 2014: Eisai Submits First Marketing Authorization Application for Anticancer agent Lenvatinib in Japan
May 31, 2014: Lenvatinib Phase III Results Show Significant Improvement In Progression-Free Survival In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
May 15, 2014: Eisai to Present Abstracts On Lenvatinib At 50th ASCO Annual Meeting
Feb 03, 2014: Phase III Trial Shows Lenvatinib Meets Primary Endpoint Of Progression Free Survival Benefit in Treatment Of Radioiodine-refractory Differentiated Thyroid Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABES

Number of Products under Development for Thyroid Cancer, H2 2014
Number of Products under Development for Thyroid Cancer - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Thyroid Cancer - Pipeline by AstraZeneca PLC, H2 2014
Thyroid Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014
Thyroid Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2014
Thyroid Cancer - Pipeline by Biovista Inc., H2 2014
Thyroid Cancer - Pipeline by centrose llc, H2 2014
Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H2 2014
Thyroid Cancer - Pipeline by Eisai Co., Ltd., H2 2014
Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H2 2014
Thyroid Cancer - Pipeline by Novartis AG, H2 2014
Thyroid Cancer - Pipeline by Translational Therapeutics, Inc., H2 2014
Thyroid Cancer - Pipeline by Trophogen, Inc., H2 2014
Thyroid Cancer - Pipeline by Vascular Biogenics Ltd., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2014
Thyroid Cancer - Dormant Projects, H2 2014
Thyroid Cancer - Discontinued Products, H2 2014

LIST OF FIGURES

Number of Products under Development for Thyroid Cancer, H2 2014
Number of Products under Development for Thyroid Cancer - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014
Skip to top


Thyroid Cancer - Pipeline Review, H1 2014 US$ 1,500.00 Jun, 2014 · 121 pages
Papillary Thyroid Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 72 pages
Follicular Thyroid Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 83 pages
Papillary Thyroid Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 106 pages
Rectal Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 107 pages

Ask Your Question

Thyroid Cancer - Pipeline Review, H2 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: